IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4739
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$159M
Thomas Zindrick
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GNLX GENELUX Corp | 26 | 23 | 34 | 13 | - | - | -157.9% | -117.5% | - | - | - | - | 0.0% | 34.0x | $159M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
GENELUX Corp (GNLX) receives a "Avoid" rating with a composite score of 26.0/100. It ranks #4739 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
No analyst ratings for GNLX.
View All RatingsVerified SEC Filings Aggregate • GNLX
Direct unfiltered access to 10-K, 10-Q and 8-K filings for GNLX.
Open Regulatory DossierFigures adjusted for stock splits and restatements where applicable.
TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.
Equity efficiency
Financial leverage
Direct cash return
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 23 | 5 | +18ALPHA |
| MOMENTUM | 13 | 5 | +8ALPHA |
| VALUATION | 34 | 23 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 34 | 21 | +13ALPHA |
| SHORT INT | 19 | 4 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -157.9% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 3yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate GENELUX Corp (GNLX) as Avoid with a composite score of 26.0/100 at a current price of $2.81. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
GENELUX Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 26.0/100 places it at rank #4739 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
GENELUX Corp represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags GENELUX Corp with an Avoid rating, assigning a composite score of 26.0/100 and 1 out of 5 stars. Ranked #4739 of 7,333 stocks, GNLX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
GENELUX Corp registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports a return on equity of -157.9% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 34/100, GNLX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 6.35x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
GENELUX Corp's investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -117.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
GENELUX Corp is experiencing notably weak momentum with a score of just 13/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.24 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
GNLX's stability score of 34/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.24 and a debt-to-equity ratio of 34.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
GENELUX Corp's short interest score of 19/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.24), elevated leverage (D/E: 34.00x), micro-cap liquidity risk. At $159M (micro-cap), GNLX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
GENELUX Corp is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4739 of 7,333 overall (35th percentile). Key comparisons include ROE of -157.9% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GNLX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (13) would have the largest impact on the composite score.
ROE 8213% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 16090% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Relative to Manufacturing Median (N=1906)
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.
Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.
No recent insider transactions available for GNLX
Institutional cap table data requires verified 13F filing feeds.
Access SEC 13F Dossier →Insider transaction data currently awaiting regulatory verification.
Access SEC Form 4 Dossier →Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Above 50MA
37.18%
Net New Highs
+51081
Genelux Corp (NASDAQ:GNLX) stock dropped 10.3% in after-hours trading following the announcement of a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares, with Lucid Capital Markets acting as the sole book-running manager. Genelux, a clinical-stage immuno-oncology company, did not disclose the terms or size of the offering, which is subject to market conditions.
Genelux Corporation (Nasdaq: GNLX) announced a proposed underwritten public offering of its common stock on January 7, 2026. The company will grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold. Lucid Capital Markets is the sole book-running manager for this offering, which is subject to market and customary closing conditions.
The biotechnology sector is emerging from a "biology winter" as Monte Rosa Therapeutics (NASDAQ: GLUE) and Genelux Corporation (NASDAQ: GNLX) successfully launched public offerings. These fundraising efforts indicate renewed investor confidence, emphasizing a "quality-first" mandate for companies with validated platforms and clear commercialization paths. This shift suggests a calculated appetite for high-upside therapeutic innovation, marking the end of the "risk-off" sentiment that dominated previous years.
H.C. Wainwright has reaffirmed its Buy rating and $31.00 price target for Genelux Corp. (NASDAQ:GNLX) following positive interim results from its cancer trials. The company's Olvi-Vec treatment, when combined with platinum chemotherapy, achieved a 33% objective response rate in small cell lung cancer patients, with strong durability data. These developments, along with a new Chief Medical Officer appointment and initiation of coverage by Lake Street Capital Markets, mark significant progress for Genelux.
Genelux (NASDAQ: GNLX) announced encouraging interim data from early trials of its experimental cancer treatment, Olvi-Vec, in patients with advanced lung cancers. The systemic administration of Olvi-Vec resulted in significant tumor shrinkage, including up to 85% in the highest dose cohort for SCLC patients, with the drug generally well-tolerated. These preliminary findings support the advancement of ongoing trials and build anticipation for additional readouts in 2026, including Phase 3 ovarian cancer results.